Introduction: Perivascular epithelioid cell tumors (PEComa) are rare tumors of mesenchymal origin that exhibit perivascular epithelioid cell phenotype. One of its most common localizations is uterus, whereas only a few studies reported PEComa localization as liver. There is a correlation between the presence of PEComa and tuberous sclerosis complex (TSC). TSC is a rare disease which leads to the development of mostly non-cancerous tumors in various organs. We would like to present a case of a kidney transplant recipient with a PEComa detected post-transplant in the liver.Case report: A 27-year-old patient, 3 years after kidney transplantation (KTx) due to chronic renal failure in the course of autosomal dominant polycystic kidney disease and concomitant TSC, was admitted to the Clinic and Department of General and Transplant Surgery for abnormal findings in computed tomography (CT). A CT scan was conducted for oncological follow-up after a kidney transplant (KTx) because before the transplantation, a small cystic lesion measuring 7 mm in diameter was removed from the donor kidney and diagnosed as papillary renal cell carcinoma (PRCC). Two tumors in the liver were detected - one 27mm in diameter in segment VII/VIII and the other 8mm in diameter in segment II/III. Because of typical radiological signs hepatocellular carcinoma was suspected, but the serum level of alpha fetoprotein was within normal limits and liver function was preserved. The intraoperative biopsy and the radiofrequency ablation (RFA) of the larger tumor were performed three months later. In the histopathological examination benign PEComa (HMB45 +, Melan A +) was detected.Conclusion: The oncological surveillance made it possible to detect liver lesion in early stage and in 3,5-year follow-up no sign of recurrence of PEComa was found. This case is the second to show RFA as treatment method of liver PEComa and first in kidney transplant recipient.
The treatment paradigm for HER2-positive metastatic breast cancer has evolved from continuous chemotherapy-based regimens to a model of finite chemotherapy induction followed by sustained antibody-driven disease control. The CLEOPATRA trial established dual HER2 blockade with trastuzumab and pertuzumab plus a taxane as the biological and clinical anchor of this approach, demonstrating that chemotherapy is administered for a defined induction period, after which antibody maintains disease suppression. An increasing body of clinical evidence indicates that antibody-based regimens can be combined with targeted agents, including CDK4/6 inhibitors or HER2 tyrosine kinase inhibitors, to achieve durable disease control without the need for continuous chemotherapy. In the PATINA trial, the addition of palbociclib to trastuzumab, pertuzumab, and endocrine therapy was associated with a clinically meaningful improvement in progression-free survival in hormone receptor-positive, HER2-positive metastatic breast cancer. At the same time, quality of life was maintained despite higher rates of hematologic toxicity. More recently, HER2-CLIMB-05 demonstrated that the addition of tucatinib to dual HER2 antibody therapy significantly prolonged progression-free survival, supporting a model of sustained, multi-agent HER2 pathway suppression. The monarcHER trial provided biological proof of concept that antibody plus CDK4/6 inhibition can achieve disease control without chemotherapy in hormone receptor-positive, HER2-positive disease. Collectively, these advances support a translational framework in which antibody therapy serves as a central component of treatment strategies, with targeted partners selected according to tumor biology and prior therapy. This review summarizes the biological basis, clinical evidence, and future perspectives of antibody-driven maintenance in HER2-positive metastatic breast cancer.
Background: A 21-year-old woman diagnosed with cystic fibrosis developed cirrhosis, exocrine pancreatic insufficiency, and insulin-dependent diabetes mellitus. The patient qualified for double organ liver–pancreas transplantation beyond typical indications. The respiratory symptoms of cystic fibrosis were moderate and well-treated. The patient was endangered mainly by liver insufficiency and recurrent hypoglycemia, which was due to the treatment of diabetes with high doses of insulin. Computed tomography showed mild bronchiectasis, cirrhotic liver, splenomegaly, and atrophy of the pancreas. Pseudomonas aeruginosa colonized the upper respiratory tract. Gastrointestinal complications were sufficient for the patient to be qualified for combined liver–pancreas transplantation. Methods: First, a standard hepatectomy was performed. The liver was transplanted orthotopically. Subsequently, the team performed pancreas transplantation through a separate incision. The donor's duodenum was anastomosed to the recipient's jejunum, close to the ligament of Treitz. Results: No serious complications were noted during the postoperative period. Transplanted organs started functioning without delay. The patient was discharged after 6 weeks in general good condition. Twenty months later, the patient felt well, and the grafts kept functioning properly. Conclusion: Combined liver–pancreas transplantation in patients with CF restores exocrine and endocrine pancreatic function and minimizes the risk of life-threatening complications associated with liver insufficiency. Improvement of life quality coincides with the possibility of discontinuing insulin and pancreatic enzyme supplementation. The combination of liver and pancreas transplantation may prevent advanced pulmonary complications, extend the prognosis of survival, and improve the long-term life quality.
Bone is the most common site of distant relapse in breast cancer, and skeletal-related events (SREs) remain a major source of morbidity and reduced quality of life in patients with bone-metastatic disease. Denosumab, a fully human IgG2 monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), interrupts osteoclast-driven bone resorption upstream of the bisphosphonate mechanism of action and has demonstrated superiority over zoledronic acid in preventing SREs in pivotal phase III trials. Beyond this well-established antiresorptive role, RANK/RANKL signaling has been implicated in mammary tumorigenesis and modulation of the tumor immune microenvironment, and recent window-of-opportunity studies have shown that short-term denosumab increases tumor-infiltrating lymphocytes in human breast tumors—a translational finding that has not yet been linked to a demonstrated clinical benefit. This narrative review synthesizes the pharmacology of denosumab; the biological rationale linking RANKL to immune-cell function in the breast; the pivotal and contemporary clinical evidence in metastatic and early breast cancer, including the divergent D-CARE and ABCSG-18 adjuvant trials and the 2026 REDUSE dosing-interval data; and practical considerations distinguishing denosumab’s evidentiary position in metastatic disease, cancer treatment-induced bone loss, and adjuvant disease modification. We also discuss why preclinical immune synergy has not been reproduced clinically and outline priorities for biomarker-selected trials, immunotherapy combinations, dose de-escalation, and MRONJ risk stratification. Throughout, we distinguish established clinical applications from translational and hypothesis-generating findings, and highlight methodological limitations—including small subgroup sizes, retrospective design, and unpublished congress data—that should temper interpretation of several recent findings before they inform clinical practice or future trial design.
Introduction: Breast cancer is the most common malignancy among women in Poland, yet participation in the national mammography screening programme remains low (approximately 30%). Medical trainees play a crucial role in promoting prevention, but their preparation in this area is insufficiently explored. Material and methods: A cross-sectional online survey was conducted among students from 10 Polish medical universities and doctors-in-training (from November 2024 to February 2025). The questionnaire assessed knowledge of screening guidelines, exposure to curricular training, and self-reported competence in clinical breast examination (CBE). Descriptive statistics and tests were used to analyse associations between categorical variables. Results: A total of 1,245 participants were included. Nearly half (48.7%) had never been taught CBE, and only 4% had practised with patients. While most respondents recognised mammography as an effective screening tool (96.4%), only 24.1% correctly identified both the screening interval and eligible age group. Attendance at curricular classes was significantly associated with better knowledge, higher confidence in performing CBE independently (p < 0.001), and greater comfort discussing breast self-examination with patients (85% vs. 76%, p < 0.001). Conclusions: This nationwide study highlights major gaps in breast cancer prevention education among Polish medical trainees. Although general awareness of mammography is high, understanding of programme details and practical CBE skills remains limited. Structured, competency-based curricula incorporating hands-on and simulation-based training are needed to strengthen preventive oncology education and support efforts to increase screening participation in Poland.